What kind of kidney injury does Chlorambucil cause?

SIADH / Hyponatremia — Inappropriate water retention at the collecting duct — high-dose cyclophosphamide. Other reported patterns: Electrolyte Disturbance.

How should kidney function be monitored during Chlorambucil therapy?

Serum sodium and osmolality if hyponatremia is suspected; CBC (dose-limiting myelosuppression); Volume status if hyponatremic; Serum sodium periodically during therapy.

How can kidney injury from Chlorambucil be prevented?

Avoid excessive hypotonic fluid intake Standard TLS precautions only if treating bulkier disease

Who is at higher risk of kidney injury from Chlorambucil?

Concurrent medications or conditions that promote SIADH; Excess free-water intake; Older age and reduced renal free-water clearance; Higher tumor burden (for the uncommon TLS scenario).

Back to explorer

Printable monograph

Alkylating agent (nitrogen mustard)

Chlorambucil

Leukeran · CLB

Alkylating agent (nitrogen mustard) · approved 1957 · 3 citations

Aging evidence· through 2021

Fairly sourced4/9 · 3 signals

Not met: 3 citations
Not met: 12+ references
Met: Accrued over 10+ years (span: 22y)
Not met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Not met: Current through 2021
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

Oral aromatic nitrogen-mustard alkylator with minimal direct nephrotoxicity; the notable renal-relevant effect is rare drug-associated SIADH/hyponatremia.

Mildearly-cytotoxic

Chronic lymphocytic leukemiaIndolent non-Hodgkin lymphomaWaldenstrom macroglobulinemiaAdvanced Hodgkin lymphoma (historical)

§01

Signature kidney injury

Signature lesion

SIADH / Hyponatremia

Chlorambucil has minimal direct nephrotoxicity. Drug-associated SIADH with hyponatremia is reported only rarely, in isolated case reports; tumor lysis is uncommon given its indolent-disease indications and gradual cytoreduction. No reliable incidence figure exists.Source: Wagner et al., Ann Hematol 1999 (case-level SIADH); incidence not quantified

Onset & rechallenge

Time to injuryVariable / unpredictable

Hyponatremia, when reported, has occurred during ongoing dosing including at low doses, with variable timing.

Distilled from: “Hyponatremia, when reported, has occurred during ongoing dosing, including with low doses; timing is variable.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

SIADH / Hyponatremia#1 · Signaturequalitative — no citable incidence
Inappropriate water retention at the collecting duct — high-dose cyclophosphamide.
Electrolyte DisturbanceSecondaryqualitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

§03

Kidney injury

Mechanism of kidney injury

No characteristic tubular or glomerular toxin. The renal-relevant signal is the syndrome of inappropriate antidiuresis: certain alkylating agents, including chlorambucil, have been linked to inappropriate ADH effect with water retention and dilutional hyponatremia. Because chlorambucil treats indolent malignancies with slow tumor turnover, clinically significant tumor lysis is unusual.

Clinical presentation

When SIADH occurs: euvolemic hyponatremia with low serum osmolality, inappropriately concentrated urine and elevated urine sodium, sometimes with nausea, confusion or seizures if severe and rapid. Otherwise kidney function typically remains stable on therapy.

Management

Manage drug-associated SIADH per standard hyponatremia principles: free-water restriction, treat severe/symptomatic cases with hypertonic saline using controlled correction rates, and reassess/withhold the offending agent. Direct nephrotoxicity management is rarely needed.Lesion-level management framework

Risk factors

Concurrent medications or conditions that promote SIADH
Excess free-water intake
Older age and reduced renal free-water clearance
Higher tumor burden (for the uncommon TLS scenario)

Prevention

Avoid excessive hypotonic fluid intake
Standard TLS precautions only if treating bulkier disease

Anticancer mechanism· how it treats cancer

Aromatic nitrogen-mustard alkylating agent that forms reactive ethyleniminium intermediates and crosslinks DNA, impairing replication and transcription in proliferating lymphoid cells and inducing apoptosis.

Note · Long-term alkylator exposure carries secondary-malignancy risk; this is a general chlorambucil safety consideration rather than a renal one.

§04

Clinical depth

Renal dose adjustment

No formal renal dose-adjustment scheme is established; chlorambucil is extensively hepatically metabolized to phenylacetic acid mustard with limited unchanged renal excretion. Dosing is guided mainly by hematologic tolerance.

Dialyzability & ESKD dosing

Not characterized as dialyzable and unlikely to be efficiently removed given rapid metabolism and protein binding; dialysis is not used for drug clearance.

Differential diagnosis

Distinguish chlorambucil-associated SIADH from hyponatremia due to other drugs, CNS involvement by lymphoma/leukemia, adrenal insufficiency, hypothyroidism, or volume depletion. Causality for chlorambucil is presumptive and based on case reports.

Monitoring

Serum sodium and osmolality if hyponatremia is suspected
CBC (dose-limiting myelosuppression)
Volume status if hyponatremic
Serum sodium periodically during therapy

Key trials & series

CLL frontline trials establishing chlorambucil as a standard oral alkylator (e.g., chlorambucil-based comparator arms); renal/electrolyte events reported only sporadically

Clinical pearls

Check the sodium, not just the creatinine: the kidney-relevant chlorambucil signal is SIADH/hyponatremia rather than AKI.
Direct nephrotoxicity from chlorambucil is minimal, and TLS is uncommon because it treats indolent, slowly proliferating disease.
Reported SIADH has occurred even at low doses, so symptomatic hyponatremia warrants reviewing the drug list.

Where it strikes· nephron segments & injury signatures

Nephron segments

Distal Tubule / Collecting Duct

Fine-tuning of Na, K, Mg, acid & water

Injury signatures

SIADH / Hyponatremia Electrolyte Disturbance

Beyond the kidney — non-renal toxicities· 3 organ systems

Class-level context for the major non-renal toxicities of the Alkylating agent (nitrogen mustard) class.

Ophthalmic

Keratopathy, uveitis, retinopathy

Visual disturbance (crizotinib)

Hepatic / Liver

Transaminitis, hepatitis, VOD/SOS

Transaminitis

Neurologic

Neuropathy, encephalopathy, ICANS, PRES

CNS effects (lorlatinib)

§05

References

3 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

3 references · 1999–2021 · 1 since 2019

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

FDA label — boxed warning & renal dosing· boxed warning

Quoted verbatim from this agent's current FDA label (Jan 2025) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING LEUKERAN (chlorambucil) can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility (see WARNINGS and PRECAUTIONS).

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 3,917 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 3 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

SIADH / Hyponatremiacorroborated · ROR 1.53 — but the naming terms alone are not disproportionate, so this rests on terms merely consistent with the lesion
Electrolyte DisturbanceNo disproportionate reporting — This phenotype IS reportable and this agent has enough reports, yet the reporting is not disproportionate — the one genuinely informative negative of the four.

Acute Interstitial Nephritis

ROR 3.7395% CI 2.16–6.42· 13 reports

Glomerular Injury / Proteinuria

ROR 2.5895% CI 1.53–4.36· 14 reports

SIADH / Hyponatremia

ROR 1.5395% CI 1.02–2.31· 23 reports

FAERS outcomes & reporting trend· 23.6% of reports w/ death · 41.5% w/ hospitalization

23.6%

Reported with a death outcome

925 of 3,917 reports

41.5%

Reported with hospitalization

1,624 of 3,917 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 7 systems · 3,917 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 1.0595% CI 0.74–1.51· 30 AKI reports ·no disproportionate AKI reporting signal (CI spans 1).

Blood & lymphatic

Neutropenia275Thrombocytopenia192Febrile Neutropenia162Anaemia157

Immune / infection

Pneumonia265Infection124Infusion Related Reaction101Sepsis89

General / constitutional

Pyrexia237Fatigue101Asthenia78Chills76

Gastrointestinal

Nausea111Diarrhoea84Vomiting84

Respiratory

Dyspnoea125

Nervous system

Progressive Multifocal Leukoencephalopathy111

Cardiac

Cardiac Disorder78

Guidelines & consensus· 14

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

ADQIConventional cytotoxic chemotherapy-associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) WorkgroupKidney Int 2026 · PMID 41881107Cisplatin is identified as a leading cytotoxic nephrotoxin; the workgroup details preventive measures (adequate isotonic hydration, correction of volume depletion, avoidance of concurrent nephrotoxins, attention to electrolyte/magnesium wasting) and management of cisplatin-associated AKI, with a research agenda for knowledge gaps.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Chlorambucil sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Melphalan

Alkeran · Alkylator

Profile

SIADH in high-dose myeloma conditioning; renally cleared.

SIADHLYTE

Mild#1 · 97% phenotype match

Temozolomide

Temodar · Alkylator

Profile

Occasional SIADH; generally renally well tolerated.

SIADHLYTE

Mild#2 · 97% phenotype match

Vinblastine

Velban · Vinca alkaloid

Profile

SIADH and rare Raynaud/vascular events.

SIADHLYTE

Mild#3 · 86% phenotype match

Vincristine

Oncovin · Vinca alkaloid

Profile

SIADH → hyponatremia.

SIADHLYTE

Mild#4 · 86% phenotype match

Vinorelbine

Navelbine · Vinca alkaloid

Profile

SIADH reports.

SIADHLYTE

Mild#5 · 86% phenotype match

Vismodegib

Erivedge · Hedgehog (SMO) inhibitor

Profile

Muscle spasms; hyponatremia reported.

SIADHLYTE

Mild#6 · 84% phenotype match

Compare Chlorambucil with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Alkylating agents

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Chlorambucil’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Chlorambucil; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 87 clinical records among all 275 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.